Pfizer's Rapamune 1st drug OK'd for lymphangioleiomyomatosis
This article was originally published in Scrip
Executive Summary
The FDA on 28 May gave Pfizer the go-ahead to market Rapamune (sirolimus) as a treatment for lymphangioleiomyomatosis (LAM), a very rare, but progressive lung disease, which primarily affects women of childbearing age.